S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

$0.07
-0.01 (-6.62%)
(As of 03/4/2024)
Today's Range
$0.07
$0.09
50-Day Range
$0.07
$0.11
52-Week Range
$0.06
$1.31
Volume
6,000 shs
Average Volume
22,874 shs
Market Capitalization
$727,056.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BLCM stock logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

BLCM Stock Price History

BLCM Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Bellicum Pharmaceuticals Inc BLCM
Futura Medical plc (FAMDF)
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
BLCM - Bellicum Pharmaceuticals, Inc.
Short Volatility Alert: Bellicum Pharma
Why Bellicum Pharmaceuticals Stock Is Plunging Today
BLCM Bellicum Pharmaceuticals, Inc.
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2021
Today
3/29/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-24,970,000.00
Pretax Margin
-1,492.40%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$0.23 per share

Miscellaneous

Free Float
8,716,000
Market Cap
$727,056.00
Optionable
Not Optionable
Beta
1.39
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. David M. Maggio (Age 64)
    Chief Executive Officer
  • Mr. Joseph Senesac (Age 54)
    Senior Vice President of Technical Operations & Quality
  • Dr. Alan K. Smith Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $536.43k

BLCM Stock Analysis - Frequently Asked Questions

How have BLCM shares performed in 2024?

Bellicum Pharmaceuticals' stock was trading at $0.15 at the beginning of 2024. Since then, BLCM stock has decreased by 50.1% and is now trading at $0.0748.
View the best growth stocks for 2024 here
.

When is Bellicum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BLCM earnings forecast
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its quarterly earnings data on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company earned $0.70 million during the quarter.

When did Bellicum Pharmaceuticals' stock split?

Bellicum Pharmaceuticals's stock reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did Bellicum Pharmaceuticals IPO?

Bellicum Pharmaceuticals (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLCM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners